Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111020 · ClinicalTrials.gov registry record · Phase 3
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,567
- Enrollment target
NCT00111020 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 2,567 participants.
The verdict
NCT00111020, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,567 participants
- Enrollment target
Study Summary
This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment. All patients in this protocol will be treated with sorafenib. In addition, data from the patients who participate in this protocol will provide additional information about the drug.
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,567 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111020
The ClinicalTrials.gov registry entry for NCT00111020 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,567 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib (Nexavar, BAY43-9006) is the first listed.
NCT00111020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111020 about?
NCT00111020 is a clinical study titled "Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma". This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial in which sorafenib is compared to a...
What is the current status of trial NCT00111020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,567 participants. The study started on 2005-06. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00111020?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00111020?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.